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HIV-2 contributes approximately a third to the prevalence of HIV in West Africa and is present in significant amounts in
several low-income countries outside of West Africa with historical ties to Portugal. It complicates HIV diagnosis, requiring more
expensive and technically demanding testing algorithms. Natural polymorphisms and patterns in the development of resistance
to antiretrovirals are reviewed, along with their implications for antiretroviral therapy. Nonnucleoside reverse transcriptase
inhibitors, crucial in standard first-line regimens for HIV-1 in many low-income settings, have no eect on HIV-2. Nucleoside
analogues alone are not suciently potent enough to achieve durable virologic control. Some protease inhibitors, in particular
those without ritonavir boosting, are not suciently eective against HIV-2. Following review of the available evidence and taking
the structure and challenges of antiretroviral care in West Africa into consideration, the authors make recommendations and
highlight the needs of special populations.
1. Introduction
HIV-2 represents a distinct lineage of HIV, stemming from
SIVsm instead of the SIVcpz responsible for HIV-1. Like
HIV-1 it appears to have made the transition to humans
more than once, giving rise to eight distinct groups, of which
groups A and B account for nearly all of the cases identified
thus far [1]. HIV-2 diers from HIV-1 most strikingly in its
lower rate of progression and infectivity, with the majority
of those infected likely to be long-term nonprogressors
[2–4]. Those with progressive disease experience the same
likelihood of morbidity and mortality as are seen with HIV-1
[5, 6]. People with advanced HIV-2 infection require treat-
ment with antiretroviral therapy (ART), but most individual
antiretroviral drugs and regimens have been designed and
optimized for HIV-1 and cannot be assumed to provide
optimal viral suppression for HIV-2 infection. In some
instances, antiretroviral susceptibility diers significantly
between HIV-1 and HIV-2, such that HIV-2 is intrinsically
resistant to two of the major classes of antiretroviral drugs:
the fusion inhibitors and the nonnucleoside reverse tran-
scriptase inhibitor- (NNRTI-) based regimens that are the
standard therapy for HIV-1 in West Africa [7, 8].
The challenge of treating HIV-2 infection falls mainly
upon West Africa [6], with current prevalence estimates
ranging up to 1% where reported, compared with HIV-1
prevalence rates of up to 3.4%, therefore comprising a
substantial portion of all HIV infections in the subregion [9].
The exception to this is Guinea-Bissau, where the prevalence
amongst adults was estimated to be 8%–10% two decades
ago [10]. This has now changed to a current prevalence
of around 4%, compared to an HIV-1 prevalence of 2.9%
in rural areas and 4.2% in urban areas [11–13]. European
countries with colonial links to West Africa such as Portugal,
France, and the United Kingdom, as well as other countries
with prior Portuguese ties, such as Angola, Brazil, India, and
Mozambique, also have sizeable cohorts of HIV-2 infected
individuals [14–18]. Although the absolute numbers of
patients infected with HIV-2 in European cohorts are small,
the earlier availability of ART in these countries has provided
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some data to guide treatment recommendations in resource-
poor settings.
Given the prevalence of HIV-2 in West Africa, it is
imperative that up-to-date recommendations be available
for the antiretroviral management of HIV-2 in these clinical
settings, characterized by the use of standardized first-,
and in some cases second-line regimens based on limited
formularies, with treatment decisions driven by protocol,
that are also highly sensitive to cost. At the time of writing,
therapeutic drug monitoring, viral load measurement, and
genotypic resistance testing are not routinely available in
West Africa, nor are coreceptor tropism assays or HLA
typing (to guide the safe use of CCR5 receptor blockers or
abacavir, resp.). The monitoring and care of HIV in sub-
Saharan Africa has, however, been a litany of barriers brought
down, and the “impossible” becomes the standard, so these
recommendations seek to strike a balance between optimal
and current management trends.
Clinical trials of ART in HIV-2 are few compared with
HIV-1, primarily because of HIV-2’s lower prevalence and
virulence, not to mention its concentration among some of
the world’s poorest people. Until there is better evidence
from randomized controlled trials, judgment of what consti-
tutes good care in HIV-2 management must therefore rely on
both in vitro as well as in vivo data from small cohort studies
and case series, theoretical assertions, and parallels with HIV-
1 therapeutics.
As will be apparent to experienced clinicians and pro-
gram ocers, numerous potential factors have been left out
of this work that might influence program-level decisions
about ART for HIV-2 in West Africa. This is especially true
where such factors aect both HIV-1 and HIV-2 infections
in the same way. The current work is not intended as an
exhaustive review of all aspects of a public health approach
to the use of ART, nor is it intended to function as an
ART primer. However, in the absence of universally accepted
treatment guidelines for HIV-2, the authors seek to provide
their own recommendations, based on the available litera-
ture, HIV-2 treatment meetings, discussions with colleagues
from major HIV-2 treatment centers in Europe and Africa,
and from personal experiences between 2003–2010 at the
Genito-Urinary Medicine clinic at the MRC Laboratories in
The Gambia, where ART was provided to HIV-2 infected
people.
2. Selecting First- and Second-Line ART
Regimes in HIV-2
2.1. Natural Polymorphisms and Patterns of Genotypic Resis-
tance in HIV-2. The most crucial dierence between HIV-1
and HIV-2 when considering suitable ART regimes is the lack
of susceptibility of the latter to what would now be called
first-generation NNRTIs, nevirapine, and efavirenz [19, 20].
The natural resistance of HIV-2 to these drugs is due to
dierences in the amino acid residues that make contact with
the NNRTI in the binding pocket of HIV-1 and HIV-2, par-
ticularly the Y181I and Y188L natural polymorphisms seen
in HIV-2, which significantly reduce NNRTI binding [7].
It is worth noting that HIV-1 mutations at these positions
result in complete resistance to NNRTIs [20, 21]. Although
etravirine is reported to have more activity against HIV-2
than previous NNRTIs, the presence of L181 and other
structural dierences in the HIV-2 NNRTI-pocket makes
HIV-2 naturally resistant to etravirine as well (reviewed in
[22, 23]).
Nucleos(t)ide reverse transcriptase inhibitors (NRTIs)
have a similar potency in both HIV-1 and HIV-2. Earlier
in vitro work demonstrating lower potency for zidovudine
(AZT) [24] appeared to be an artifact of the assay used,
and more recent work demonstrates similar potency in both
HIV-2 and HIV-1 [25]. The development of NRTI resistance
in HIV-2 shares many parallels with that in HIV-1, although
key dierences are worth highlighting that are of clinical
relevance. The M184V mutation occurs rapidly, both in vitro
[26] and in vivo [27] in approximately 83% of patients failing
a lamivudine (3TC)-containing regimen [28, 29]. As in
HIV-1, it is associated with high-level phenotypic resistance
to 3TC and emtricitabine (FTC) in HIV-2-infected individu-
als [30]. Although HIV-1 and HIV-2 share some classic NRTI
resistance patterns, the preference for alternative resistance
pathways has been noted, in addition to unique resistance
patterns in HIV-2. AZT resistance in HIV-1 occurs via
two well-documented pathways. The most common and
preferred pathway is marked by the accumulation of the
six thymidine-associated mutations (TAMs): M41L, D67N,
K70R, L210W, T215Y, and K219Q/E [31]. The less common
pathway is via the Q151M mutation, which also tends to
develop later. The TAM mutations are conspicuously absent
in the AZT resistance profiles of HIV-2 patients [27, 28,
32–35]. In place of TAMs, AZT resistance in HIV-2 often
involves the Q151M mutation, which occurs faster and with a
much higher frequency and potency than in HIV-1 [30, 36].
Considering that this mutation causes multi-NRTI resistance
in HIV-2, its high frequency raises real concerns [29, 37].
Unlike HIV-1 where K65R leads to TDF, ABC, ddI, and d4T
resistance [38], K65R in HIV-2 does not cause phenotypic
resistance to TDF, but causes high-level resistance to 3TC and
FTC, and low-level resistance to ddI [30]. Current evidence
suggests that this mutation rarely occurs in HIV-2 except
during suboptimal mono- or dual-therapy with NRTIs that
mostly do not include TDF [27, 39, 40], where it is often
associated with the Q151M mutation. There is, however,
limited experience with widespread use of TDF containing
regimes in first-line HIV-2 ART, and firm conclusions on
a reduced frequency of K65R in HIV-2 infection cannot
be drawn with confidence. Of note, in a recent Senegalese
study, two (of 23) patients exhibited K65R mutations at
follow-up while on an AZT/3TC/indinavir (IDV) regimen,
although in one case the mutation was present at baseline
prior to commencing ART [35]. These data together with
the phenotypic data by Smith et al. [30] indicate that K65R
arises primarily due to 3TC/FTC pressure in HIV-2. The
potential fragility of currently available NRTI backbones for
use in HIV-2 therapy is highlighted by the finding that
Q151M combined with K65R or M184V results in high-
level AZT and 3TC resistance, whereas the presence of all
three mutations in combination confers class-wide NRTI
resistance, although it should be noted that these mutations
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result only in low level resistance (4-5 fold) to d4T and
TDF [30]. Lastly, the L74V mutation is rarely documented
in HIV-2 [41], with one report of L74I in an HIV-2-infected
patient on dual therapy (which included ddI) [40].
HIV-1 and HIV-2 proteases have an amino acid sequence
similarity of about 50%, substantially less than that observed
in their reverse transcriptase enzymes. These sequence dier-
ences are reflected in very distinct natural polymorphisms in
the HIV-1 and HIV-2 proteases, most of which occur outside
the functionally relevant areas [42]. Several HIV-2 natural
polymorphisms correspond to drug resistance mutations in
HIV-1. These include the major drug resistance mutation
M46I, conferring resistance to indinavir (IDV), and several
minor mutations, L10V, V32I, M36I, I47V, A71V, and G73A,
that may decrease the activity of nelfinavir (NFV) and
amprenavir (APV) [32, 43–46]. Several in vitro cultural and
cell-free assays using individual PIs have suggested that while
IDV, saquinavir (SQV), lopinavir (LPV), darunavir (DRV),
and tipranavir (TPV) may exert full activity against wild-type
HIV-2 [47–52], NFV and APV show a significant reduction
in activity [46, 53]. A more in-depth study (kinetic inhibition
assays) has shown that LPV, SQV, TPV, and DRV exhibit
the highest potency in this order and that atazanavir (ATV),
NFV, and APV show the lowest potency, respectively [54].
The data on TPV are however controversial, with other
studies showing several fold lower potency when compared
to LPV, SQV, and DRV [55, 56]. Once protease inhibitor-
(PI-) based ART starts, this background of minor mutations
may result in rapid acquisition of a multi-PI resistance
phenotype [45, 46].
In HIV-1, PI resistance is associated with the accu-
mulation of four or more resistance mutations in the
protease gene, though major mutations can cause substantial
resistance on their own [57]. HIV-1 and HIV-2 have similar
PI resistance mutations [33, 43, 45, 46, 53], with a few muta-
tions unique to HIV-2 [20, 45, 46]. The presence of certain
natural polymorphisms in HIV-2 can reduce the time to
resistance in some cases [34, 46]. For instance, I47A and V32I
are associated with high-level resistance to LPV/ritonavir
(LPV/r) in HIV-1 [58–60], and V47A is associated with
phenotypic resistance to LPV/r in HIV-2 [61]. In HIV-1, the
emergence of the LPV/r mutation I47A is a two-step process
(I → V → A), whereas in HIV-2 it can occur in a single step
from V → A [61]. In addition, V321 is present naturally in
HIV-2. Therefore while LPV/r resistance in HIV-1 requires
the acquisition of V32I and a two-step process to acquire
I47A, only a one-step change in HIV-2 is required, making
the development of this mutation easier and faster in HIV-2
[34].
2.2. Potential Options for Standardized First- and Second-
Line Regimes in Resource Poor Settings. Until recently, most
studies reporting antiretroviral use in HIV-2 patients were
from European cohorts, and often involved mono- or dual-
therapy and multiple heterogeneous regimens [28, 32, 33, 40,
62]. Due to the recent availability of ART in West Africa,
data from the use of standardized first-line ART regimens
in these cohorts are now appearing [34, 35, 63], although
the numbers are still relatively small when compared to
the HIV-1 literature. Given the lack of utility of NNRTIs
in HIV-2, a key issue in choosing first-line ART regimes
in HIV-2 infection is the question of whether triple NRTI
regimens are a viable, safe, and ecacious option. The appeal
of this approach lies in its lower pill burdens and reservation
of PIs for second-line therapy, maintaining parallels with
HIV-1 protocols. Prior to the development of a heat stable
formulation of ritonavir, and in settings where this is not
yet available, cold chain requirements also argue for a PI-
sparing regimen. Unfortunately studies to date suggest that
these regimes, including those with TDF, perform poorly in
HIV-2 [28, 62, 64] and in our opinion should be avoided,
although in certain specific circumstances they may represent
the best balance of risk and benefit (see special populations,
below). One case of a patient achieving viral suppression on
a quadruple NRTI regimen (d4T/3TC/ABC/TDF) has been
reported [62], although clearly more evidence is needed to
conclude that such a regimen is superior to using triple
NRTIs in HIV-2. The principal challenge of the PI-sparing
nucleoside regimens in HIV-2 is the rapid development of
the Q151M pan-NRTI resistance mutation [36]. Unlike the
case in HIV-1 where this typically arises only after multiple
other resistance mutations have developed, in HIV-2 it is
one of the earliest and most common NRTI mutations
(after those at the M184 locus), especially after mono-/dual-
/triple-NRTI treatment [28, 32, 33, 40, 62] and compromises
the entire regimen [36]. Triple nucleotide regimes containing
ABC (in the absence of TDF) have also been shown to rapidly
select for K65R in HIV-2 patients [64].
Our experience at the MRC Gambia [34] and that of
others [62, 65] suggest that the combination regimen of
AZT/3TC and LPV/r has a reasonable chance of success
as a first-line regime for HIV-2 infection [34, 62, 65].
The use of an AZT/3TC backbone with unboosted IDV,
however, has been shown to result in a high proportion
of ART failures and accumulation of resistance mutations
in a Senegalese cohort [35, 56]. ABC/3TC, TDF/FTC, and
ddI-based regimens have the advantage of daily dosing and
show potential for success, although in our opinion there
is currently insucient experience with those combinations
in HIV-2 to draw firm conclusions. Moreover the inclusion
of appropriate PIs in HIV-2 regimes will necessitate twice
daily dosing in most circumstances, reducing the benefit
of once-daily nucleoside analogue dosing. Didanosine also
has a rather unique set of advantages and disadvantages as
part of ART regimes. It should generally be taken on an
empty stomach while other antiretrovirals, in particular TDF,
should be taken with food, adding to regimen complexity.
We believe ddI is less well tolerated than ABC, AZT, TDF,
or 3TC and that this could threaten patient adherence to the
overall regimen. Its use with TDF is relatively contraindicated
because of the negative impact this combination has on
CD4 cell counts and the increased risk of viral failure
[66], even at the appropriate 250 mg dose [64]. Although
no head-to-head comparisons have been performed in
HIV-2-infected individuals, the HIV-1 literature suggests
that an NRTI backbone of TDF/FTC (or 3TC) may, on
the grounds of ecacy and tolerability, be a better choice
than AZT/3TC [67, 68] or ABC/3TC [69, 70]. On that
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basis, TDF may be desirable in first-line treatment in spite
of its greater cost when compared with AZT (see Table 2),
although the low yet measurable risk of renal toxicity with
TDF use, particularly in settings where renal monitoring may
be limited, is grounds for concern [71]. Tolerability issues
should also be considered. If a patient does not tolerate
AZT in first-line treatment other alternatives (including d4T)
could be used, following the same protocols as are used
for AZT intolerance in HIV-1-infected individuals; however
an equivalent substitute for TDF in the face of resistant
virus is not easy to find in the event of TDF intolerance.
Given that the prevalence of HLA B∗5701 is low in black
African individuals [72], with HLA∗B5703 being the only
B57 subtype found in populations in Guinea-Bissau [73], the
risk of ABC hypersensitivity, if ABC/3TC is used first line
without the ability to determine HLA type, may not be of
great concern in sub-Saharan Africa.
As mentioned above, PI options are constrained in
HIV-2 as a result of natural polymorphisms that support
PI resistance. In addition, unboosted PI regimens should
be avoided as they tend to perform poorly [29, 35, 40, 56].
While good clinical outcomes with LPV/r have been observed
[34, 65], in vitro data [54] suggests that SQV/r would be a
reasonable first-line PI [54] too, while IDV/r may also be
eective [28]. DRV/r would appear to be reliable based on
in vitro data, although at present there is insucient data
to justify its use as the preferred first-line PI for HIV-2
given its higher cost (see below). Boosted ATV cannot be
recommended in HIV-2 [54, 55], and given the conflicting
results on the use of boosted TPV [54–56], it also cannot
be recommended for use until further studies confirm its
ecacy.
Second-line therapy should be considered in drafting
treatment guidelines for first-line ART, as initial regimen
choices narrow later treatment options. In the absence of
viral load monitoring, resistance should be anticipated at
the time of regimen change, and we make the assumption
that resistance test results will not generally be available.
Two fundamentally dierent strategies in ART are to increase
potency up-front in order to minimize failure rates, or to
hold potent antiretrovirals in reserve in order to mitigate
the impact of failure of the first-line. Knowledge of typical
mutations selected for during failure allows one to optimize
sequential treatment, although HIV-2 is much less well
studied in terms of the frequency with which various
sequential regimens select for resistance mutations.
With regards to NRTIs, extensive resistance should be
assumed to include the Q151M, K65R, and M184V, depend-
ing on the NRTIs employed in the first-line ART. While ABC
is probably an option where only the Q151M mutation is
present, it would be compromised in the presence of K65R
and M184V [30]. Older NRTIs including AZT and ddI are
not likely to have much residual potency in the face of these
mutations; however TDF and d4T might retain sucient
potency in this setting [30]. The argument that the M184V
mutation carries a substantial fitness cost has not been
demonstrated as clearly in HIV-2 as it has in HIV-1 [75],
nonetheless as it occurs in the highly conserved YMDD motif
within the reverse transcriptase’s active site [76], we believe
it is likely to aect fitness similarly, and we recommend
continued exposure to 3TC or FTC in order to maintain the
M184V.
Based on the resistance data described earlier, recom-
mended first-line boosted PIs for HIV-2 in resource limited
settings are LPV/r, SQV/r, and possibly IDV/r. It appears
that HIV-2 V47A mutants, selected for by failure on a LPV/r
regimen, retain susceptibility to other PIs and are in fact
hypersusceptible to ATV and SQV [61]. We find that this
makes SQV/r an attractive choice for second-line therapy to
follow up LPV/r-based ART in HIV-2.
Given the more limited range of eective antiretrovi-
rals, both biologically and as a consequence of HIV-2’s
disproportionate prevalence in the resource-limited settings
of West Africa, second-line treatment in HIV-2 becomes
markedly challenging. Going back to the broader question
of strategy, we support a boosted PI in the first regimen
because we believe that failure rates on triple NRTI regimens
are unacceptable. Nonetheless we recommend TDF be held
in reserve to lend potency to second-line treatment.
2.3. HIV-1/HIV-2 Dual Infection. Co-infection with both
HIV-1 and HIV-2 occurs in countries where both viruses
circulate. Although progression, as implicated by higher
viral loads, is driven by HIV-1 in the majority of dually
infected individuals [77], this is not always the case [34].
Treatment of dually infected individuals should be carried
out using an HIV-2 regimen, to ensure that the drugs used
can eectively treat both viruses [34, 78]. Given that the
HIV-2 plasma viral load is usually undetectable or low
in dual infections, it might seem reasonable to treat and
monitor only HIV-1 (discussed in [79]). In our opinion this
represents a dangerous strategy, as even with an undetectable
baseline HIV-2 VL, the risk exists that as HIV-1 is controlled
and CD4+ T-cell targets expand, the potential for HIV-
2 replication will also increase [78]. In addition, we have
successfully treated eight dually infected individuals on
an HIV-2 regimen of AZT/3TC/LPV/r achieving complete
suppression of both viruses for more than three years [34].
Taken together, Tables I(a) and I(b) show possible com-
binations that would be likely to optimize control of HIV-2
in mono- and dual-infections, across two regimens, with the
authors’ preference given in bold.
2.4. Other Agents. While some newer agents developed for
use against HIV-1 show no activity against HIV-2 and
other products are currently unrealistic options in resource
poor settings, they warrant discussion even if they lie far
outside the protocols and budgets of West African treatment
programs currently. With potentially increasing numbers of
HIV-2 infected patients with first-line (and perhaps second-
line) regimen failures in West Africa, increasing experience
with the use of newer agents in salvage therapy in European
settings and, hopefully, the costs of newer agents dropping
over time, HIV-2 ART guidelines will require frequent
reconsideration and updates.
Two types of entry inhibitors, fusion inhibitors (FI)
and coreceptor binding inhibitors, have been approved for
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Table 1
(a) Potential first- and second-line NRTI backbones for HIV-2 and dual
infection
First-line Second-line
AZT/3TC TDF/AZT/3TC or FTC
TDF/FTC or 3TC∗ TDF/AZT/3TC or FTC
ABC/3TC TDF/AZT/3TC or FTC
∗
FTC and 3TC are assumed to be essentially equivalent in the table, despite
FTC’s possible superiority and 3TC’s possibly lower cost.
(b) Potential first- and second-line PIs for HIV-2 and dual infection
First-line Second-line
LPV/r SQV/r or DRV/r
SQV/r LPV/r or DRV/r
IDV/r LPV/r or SQV/r or DRV/r
Table 2: Representative daily costs of selected antiretrovirals in
West Africa in 2010 [74]. All values represent amounts paid since
01/01/2010 in West Africa except where otherwise noted, in which
case the nearest equivalent in terms of year of purchase and income
was used.
Drug Cost per daya
AZT/3TC $0.28–$0.36
d4T/3TC $0.12
ABC/3TC $1.38b
ddI (400 mg buered) $0.79
3TC $0.08–$0.10
TDF $0.72c
TDF/FTC $0.87–$0.88c
LPV/r $1.24–$1.56d
IDV $0.96d
SQV $7.20e
DRV $22.12–$28.40f
Ritonavir (100 mg bd) $0.22–$0.96d
a
Costs are given in US dollars for standard doses given twice daily or daily
in the case of TDF, ddI, ABC/3TC, and TDF/FTC
bDominican Republic; 2008
cRepublic of South Africa, Somalia
d2009
eEgypt
f Bulgaria, Jamaica; 2009.
HIV therapy. Enfurvitide (T20), a fusion inhibitor currently
licensed for use in HIV-1, has been found to have no
activity against HIV-2 [8] which is not surprising given
that HIV-1 and HIV-2 only share an amino acid sequence
similarity of less than 30%–40% in the Env protein [80].
Maraviroc, a coreceptor binding inhibitor, works by blocking
the CCR5 receptor, thereby inhibiting the virus from further
conformational changes that will allow fusion with the
host membrane. The activity of maraviroc against HIV-2
has not been formally tested, but since this drug binds to
the CCR5 receptor, it should work against R5-tropic HIV-
2 viruses [81, 82]. A recent case report demonstrates the
inclusion of maraviroc in a regime used successfully to
control resistant HIV-2 infection [83]. However, the ability
of HIV-2 eciently to utilize other coreceptors may limit
the eectiveness of these antagonists in HIV-2 treatment
[84]. Another potential concern is the switch or emergence
of X4-tropic viruses, which is associated with faster disease
progression [84]. Although R5 to X4 switch has only
been reported in a few HIV-2-infected individuals [85], a
limited number of X4-tropic viruses have been isolated from
symptomatic patients [80].
Integrase inhibitors (INIs) work by interfering with
the insertion of HIV DNA into host DNA and raltegravir
(RAL), the first licensed INI for HIV-1 therapy, appears to
be safe and ecacious in both ART naı¨ve [86] and ART-
experienced patients [87]. Despite the 40% heterogeneity in
HIV-1 and HIV-2 integrase genes, the functionally important
motifs (the catalytic triad DDE, the HHCC, and RKK) are
100% conserved in HIV-1 and HIV-2 [88, 89]. In vitro
susceptibility of 14 clinical HIV-2 isolates, as well as HIV-2
ROD, to RAL, has showed similar activity for HIV-1 and
HIV-2 [88]. In vivo studies on highly treatment-experienced
HIV-2-infected individuals, two with group A [88, 90] and
one with group B [91], showed promising results, with
viral loads reduced to undetectable results, when RAL was
used in combination therapy. HIV-2 resistance to RAL in
vivo occurs via the N155H mutation [91] which is also
associated with phenotypic resistance against RAL in HIV-2
[92]. However, these HIV-2 N155H mutants, like the M184V
mutation in the reverse transcriptase, are much less fit than
the wild type [75, 92]. This loss in replicative capacity can
be exploited when viral suppression is no longer a realistic
goal of therapy, and maintaining these mutations through
continued selective pressure can slow disease progression.
3. Special Circumstances
3.1. Pregnancy. While the risk of HIV-2 transmission in
pregnancy only reaches about 4% (including breast milk
transmission) [93], clinical and in vitro data would suggest
that AZT monotherapy as part of a prevention of mother
to child transmission program poses a considerable threat
to the mother, and to the child in the event of infection,
of selecting for the Q151M mutation with subsequent pan-
NRTI resistance [36]. Boosted PI-based ART through the
latter two trimesters of pregnancy and the breastfeeding
period should be the mainstay of vertical transmission
prevention; however boosted PIs may result in greater nausea
or insulin resistance in a small number of patients [94].
Dosing of PIs in pregnancy is not well validated, with
evidence of reduced plasma concentrations with several
agents, especially when used unboosted [95, 96]. Recent
findings suggest that in the absence of TDM, LPV/r dose
should be increased 50% in the second and third trimesters
of pregnancy [97]. SQV/r is probably eective at its standard
dose of 1000/100 mg twice daily [98, 99] and IDV/r at its
standard dose of 800/100 mg twice daily may be adequate,
but further clarification is required [100]. As with HIV-1,
concerns exist about the use of TDF as part of the nucle-
oside backbone during pregnancy potentially interfering
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with bone mineralization, although it has not as yet been
associated with congenital abnormalities [101].
3.2. Tuberculosis (TB) Coinfection. TB is endemic in West
Africa, and the problematic drug interactions between
PIs and rifampin are well known, with induction of the
cytochrome P450 system by rifampin resulting in accelerated
metabolism of PIs, making eective dosing of the PIs more
dicult to achieve. Provision of rifabutin as part of TB
therapy for HIV-2 co-infected patients would therefore be
ideal, allowing for the more predictable pharmacokinetic
interactions between LPV/r and rifabutin. However TB treat-
ment protocols, particularly where TB and HIV treatments
are managed by dierent health care providers, might not
adopt rifabutin as a result of cost or other considerations.
In this case, where ART cannot be safely deferred, a PI-
sparing regimen may represent the best balance of safety and
ecacy for HIV-2/TB co-infected patients. Increasing the PI
dose, for example doubling the dose of LPV/r, may be an
alternative, although achieving therapeutic drug levels with
tolerable dosing of LPV/r appears challenging [102, 103]. If
a triple or quadruple NRTI regime is used, ART should be
reassessed once TB treatment is completed and the patient
switched to a boosted-PI regimen.
3.3. Chronic Hepatitis B (HBV) Co-Infection. Chronic HBV
infection is common in West Africa, with prevalence rates
of 8%–20% [104–106]; as a consequence many individuals
infected with HIV-2 can be expected to have chronic HBV co-
infection and a substantial proportion is likely to have high
HBV viremia. Unlike the epidemiology in Western countries,
most HBV transmission occurs between children and is
not due to shared risk factors for transmission as between
sexually active or intravenous drug using adults [107].
Screening protocols for comorbidities in HIV care settings
in HBV endemic countries should include HBsAg, either for
all new patients or at a minimum for those with evidence
of liver disease, such as transaminitis. Where chronic HBV
is present, ideally TDF/FTC or TDF/3TC should be in the
first-line ART regimen [108], although this recommendation
may be dicult to follow where HBV diagnostics are limited.
Moreover it introduces another layer of complexity into
protocol-based sequential ART. Clearly these issues would
be addressed if TDF/FTC (or 3TC) were adopted as the
preferred NRTI backbone, although it may be necessary to
maintain them in succeeding regimens, regardless of the
addition of other agents, to avoid the risk of HBV “flare”
arising with their discontinuation [109].
3.4. Childhood. Children with HIV-2 infection present many
of the same challenges as those with HIV-1 infection, such
as concerns about dosing, formulations, and specifically
TDF toxicity [110]. The principal dierences, that vertical
HIV-2 transmission is distinctly less common and that it
is not rare for perinatal HIV-2 infections to present in
teenagers, do not argue for any specific dierences in their
management compared to children with HIV-1, beyond
their antiretroviral regimen being appropriate for HIV-2 as
described above for adults.
4. Operational Issues
Endemic HIV-2 brings with it complications in terms of
program management in West Africa beyond the necessary
alterations in the antiretroviral therapy protocols, specifically
that it complicates HIV testing and management of both
stocks and sta.
4.1. Diagnosis. Testing to distinguish HIV-1 from HIV-2 and
dual infection can be complicated and expensive due to the
presence of cross-reactive antibodies and strain dierences
[111, 112]. Screening tests need high sensitivity for HIV-
2, while confirmatory testing may require multiple steps in
order to reliably distinguish between HIV-1, HIV-2, and
HIV-1/HIV-2 dual infection, detailed review of which is
beyond the scope of this paper. The alternative to these more
demanding and elaborate testing protocols is misdiagnosis,
primarily over-diagnosis of HIV-1/HIV-2 dual infection,
resulting in HIV-1 monoinfected people going onto more
expensive and cumbersome PI regimens. Diagnostic clarity
therefore is a trade-o between higher upfront costs in
testing and savings over the longer term in pharmaceuticals,
although no rigorous analysis of costs has yet been made in
this context. Misdiagnosis that results in HIV-2 and dually
infected patients going on treatment that ignores their HIV-2
carries a greater risk, as discussed earlier.
4.2. When to Start. Compared with HIV-1, more patients
with HIV-2 will be long-term nonprogressors or slow
progressors. Although this could be used to argue for a later
CD4-driven initiation of ART, it has been demonstrated that
immunological recovery on ART is worse in HIV-2 com-
pared with HIV-1 [113] and excessive delay in initiating ART
may carry long-term negative immunological consequences.
While the authors support initiating treatment for HIV-2
below a CD4 count of 350/mm3 or possibly higher, instead
of below 200/mm3, it may be operationally awkward to apply
dierent CD4 cut-os for starting ART in HIV-1 and HIV-2
where CD4-driven initiation of therapy has not yet advanced
to the earlier thresholds.
4.3. Monitoring. There is little evidence to suggest that
monitoring of patients on ART should be any dierent
for HIV-2 than for HIV-1. In practice the lack of a
commercially available viral load assay [114] makes viral load
measurements harder to obtain for HIV-2. CD4 recovery has
been found to be blunted in HIV-2 [113]; combined with the
more limited treatment options for HIV-2 this argues against
considering a lack of substantial CD4 gains on ART to be a
failure. Other immunologic criteria, including a drop from
peak or a return to baseline CD4, may not be any worse for
monitoring response to treatment in HIV-2 than in HIV-1.
4.4. Stock Management. In terms of stock management,
the more complicated the program, the more dicult it
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will be to avoid stock shortages and wastages. Endemic
HIV-2 complicates the program. The numbers of HIV-2
patients needing ART are harder to estimate and may vary
with changes in testing algorithms (see Section 4.1). As
HIV-2 patients on ART will represent a small minority of
a program or project’s total number of HIV patients, small
fluctuations in their number result in disproportionately
large fluctuations in utilization rate, a situation that is
further exacerbated for second-line treatment and pediatric
cohorts. Stock management for pediatric cohorts with their
heterogeneity in terms of weight, physical maturity, and
ability to swallow pills is particularly dicult, and pediatric
HIV-2 cohorts are likely to be extremely small. Partial
standardization across both HIV-1 and HIV-2 regimens, for
example using the same NRTIs regardless of HIV type or
using the same PI for HIV-2 first-line treatment that one
uses for HIV-1 second-line treatment, may simplify stock
management and reduce shortages and wastage.
Another factor aecting ART choices in West Africa is
cost. While costs can be expected to vary over time and
between countries or regions, representative daily costs for
several combinations, primarily from West Africa in 2010,
are given in Table 2, although neither the costs nor the
ratios of costs that follow should be presumed to be static.
Compared with AZT, TDF and ddI are 2-3 times and ABC
4-5 times as expensive, while d4T costs half to one-third
as much. The most expensive part of the regimen is the
boosted PI, and this is also the main source of cost dierences
between regimens. Compared to coformulated LPV/r, SQV/r
is 5–7 times and DRV/r 14–23 times as expensive, while
IDV/r is approximately of the same cost. Comparisons of
costs should also take ecacy into account. Depending on
the model and assumptions this may result in medicines with
a higher daily cost being more cost-eective, as has been
recently shown for TDF in first-line ART in India [115].
4.5. Training and Protocol Development. The dierences in
recommendations between HIV-1 and HIV-2 and the dosing
complications, particularly with TB cotreatment and in late
pregnancy, pose further challenges to front line sta involved
in program implementation in the HIV-2 endemic areas
of West Africa. More complicated protocols call for more
detailed training of sta. Greater diagnostic ambiguity and
a broader range of ART regimens require more complete
medical records. Finally patients getting information from
various sources, especially long-term nonprogressors, need
additional counseling to understand their disease.
5. Summary Recommendations
West African and other programs faced with HIV-2 patients
need locally adapted protocols for testing, treatment, moni-
toring, and stock management in order to be eective.
With regards to treatment, the delivery of optimal therapy
should be a program goal, and although more complicated,
it is achievable within a public health framework, with
nurse-led clinics, even where infrastructural or stang
deficits may exist. For adults with HIV-2 or HIV-1/HIV-2
dual infection without access to ART susceptibility testing,
optimal antiretroviral therapies for first- and second-line
treatment are suggested in Tables I(a) and I(b). It is hoped
that these recommendations will rapidly become obsolete as
other agents and drug classes come into wider use in West
Africa, and prospective randomized controlled trials of ART
in HIV-2 provide more reliable indications of the suitability
of specific regimens.
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